Hemostemix Inc. (HEM.V)
CAD 0.1
(26.67%)
CAD 0.1
(26.67%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -2.5 Million CAD | 52.21% |
| 2022 | -5.23 Million CAD | 16.71% |
| 2021 | -6.28 Million CAD | 19.09% |
| 2020 | -7.76 Million CAD | -59.52% |
| 2019 | -4.86 Million CAD | 21.3% |
| 2018 | -6.18 Million CAD | -57.25% |
| 2017 | -3.93 Million CAD | -3.97% |
| 2016 | -3.78 Million CAD | 5.03% |
| 2015 | -3.98 Million CAD | 8.02% |
| 2014 | -4.33 Million CAD | -181.24% |
| 2013 | -1.54 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -519.34 Thousand CAD | -9.21% |
| 2024 Q1 | -475.53 Thousand CAD | 30.44% |
| 2023 Q1 | -1.27 Million CAD | 5.27% |
| 2023 Q4 | -683.58 Thousand CAD | -165.74% |
| 2023 Q3 | -257.24 Thousand CAD | 9.72% |
| 2023 FY | -2.5 Million CAD | 52.21% |
| 2023 Q2 | -284.94 Thousand CAD | 77.68% |
| 2022 Q1 | -1.63 Million CAD | 49.14% |
| 2022 FY | -5.23 Million CAD | 16.71% |
| 2022 Q2 | -1.44 Million CAD | 11.59% |
| 2022 Q3 | -810.52 Thousand CAD | 43.94% |
| 2022 Q4 | -1.34 Million CAD | -66.24% |
| 2021 Q2 | -1.34 Million CAD | -96.23% |
| 2021 Q4 | -3.21 Million CAD | -207.76% |
| 2021 Q1 | -683.7 Thousand CAD | 82.86% |
| 2021 Q3 | -1.04 Million CAD | 22.12% |
| 2021 FY | -6.28 Million CAD | 19.09% |
| 2020 FY | -7.76 Million CAD | -59.52% |
| 2020 Q4 | -3.98 Million CAD | -147.25% |
| 2020 Q3 | -1.61 Million CAD | 20.33% |
| 2020 Q2 | -2.02 Million CAD | -1344.58% |
| 2020 Q1 | -140.2 Thousand CAD | 77.07% |
| 2019 FY | -4.86 Million CAD | 21.3% |
| 2019 Q3 | -1.36 Million CAD | -2.69% |
| 2019 Q2 | -1.32 Million CAD | 15.51% |
| 2019 Q4 | -611.45 Thousand CAD | 55.11% |
| 2019 Q1 | -1.56 Million CAD | 9.73% |
| 2018 FY | -6.18 Million CAD | -57.25% |
| 2018 Q4 | -1.73 Million CAD | -1.96% |
| 2018 Q2 | -1.65 Million CAD | -53.1% |
| 2018 Q1 | -1.08 Million CAD | -17.65% |
| 2018 Q3 | -1.7 Million CAD | -2.79% |
| 2017 Q2 | -509.8 Thousand CAD | 7.1% |
| 2017 Q4 | -921.2 Thousand CAD | 62.63% |
| 2017 Q3 | -2.46 Million CAD | -383.51% |
| 2017 FY | -3.93 Million CAD | -3.97% |
| 2017 Q1 | -548.75 Thousand CAD | 36.05% |
| 2016 FY | -3.78 Million CAD | 5.03% |
| 2016 Q2 | -636.76 Thousand CAD | 7.26% |
| 2016 Q3 | -1.6 Million CAD | -151.73% |
| 2016 Q4 | -858.16 Thousand CAD | 46.46% |
| 2016 Q1 | -686.63 Thousand CAD | 40.98% |
| 2015 Q1 | -888.88 Thousand CAD | 58.0% |
| 2015 FY | -3.98 Million CAD | 8.02% |
| 2015 Q4 | -1.16 Million CAD | -19.27% |
| 2015 Q3 | -975.44 Thousand CAD | -1.89% |
| 2015 Q2 | -957.37 Thousand CAD | -7.71% |
| 2014 FY | -4.33 Million CAD | -181.24% |
| 2014 Q1 | -9107.00 CAD | 41.46% |
| 2014 Q3 | -888.2 Thousand CAD | -2316.02% |
| 2014 Q2 | -36.76 Thousand CAD | -303.68% |
| 2014 Q4 | -2.11 Million CAD | -138.27% |
| 2013 Q3 | -16.31 Thousand CAD | 53.03% |
| 2013 FY | -1.54 Million CAD | 0.0% |
| 2013 Q1 | -51.57 Thousand CAD | 0.0% |
| 2013 Q4 | -15.55 Thousand CAD | 4.65% |
| 2013 Q2 | -34.73 Thousand CAD | 32.65% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Arch Biopartners Inc. | -3.32 Million CAD | 24.788% |
| Covalon Technologies Ltd. | -4.46 Million CAD | 43.911% |
| Universal Ibogaine Inc. | -10.49 Million CAD | 76.162% |
| Kane Biotech Inc. | -5.03 Million CAD | 50.297% |
| MedMira Inc. | -2.67 Million CAD | 6.486% |
| Marvel Biosciences Corp. | -2.29 Million CAD | -9.196% |
| NervGen Pharma Corp. | -22.38 Million CAD | 88.821% |
| XORTX Therapeutics Inc. | -2.85 Million CAD | 12.494% |